Dr. Thomas K. Weber Colorectal Cancer Research Scholar Award
The Colon Cancer Foundation and the SSO developed this award in 2011 to recognize excellence in translational research focused on the molecular biology of colorectal cancer. This award was renamed in 2020 to honor the late Dr. Thomas Weber, the Colon Cancer Foundation’s founder. This award is made annually to a postdoctoral surgical oncology fellow whose work is being presented at the International Conference on Surgical Cancer Care and includes a grant to a postdoctoral surgical oncology trainee to help underwrite their research.
2024: Poster 16: Lymphocyte Density Analysis in Appendiceal Cancer Reveals CD8: CD3 Ratio as a Grade-Independent Prognostic Biomarker, Chelsea M. Knotts, MD
2023: Poster 24: Sufficient Regional Lymph Node Examination for Staging High-Grade Appendix Cancer, Felipe Lopez-Ramirez, MD
2021: Oral Paper 21: Circulating Hybrid Cells as a Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers, Brett S. Walker, MD, Oregon Health & Science University, Portland, OR
2020: Ten Year Survival After Pathologic Complete Response in Rectal Adenocarcinoma, Naomi Sell, MD, Massachusetts General Hospital, Boston, MA
2019: Oral Paper 43: Spatial Characterization of the Metastatic Colon Cancer Immune Microenvironment Identifies Potential Candidates for Immunotherapy, Jenny Lazarus, MD, University of Michigan
2017: Oral Paper 50: Anti-KRAS siRNA Nanoparticles for Targeted Colorectal Cancer Therapy, Bradley A. Krasnick, MD, Washington University School of Medicine, St. Louis, MO
2016: Oral Paper 83: Race-Based Socioeconomic and Treatment Disparities in Adolescent and Young Adults with Stage II-III Rectal Cancer, David Y. Lee, MD, John Wayne Cancer Institute, Los Angeles, CA
2015: Poster P143: Genetic Analysis of Colorectal Cancers in Young Patients, Andrea Abbott, MD, MS, H. Lee Moffitt Cancer Center, Tampa, FL
2014: Oral Paper 18: Isolated Tumor Cells are a Negative Prognostic Factor in Disease-free and Overall Survival in Stage I & II Colon Cancer Patients: A Propensity Score Analysis, Benjamin Weixler, MD, Department of Surgery, University Hospital, Basel, Switzerland
2013: Oral Paper 17: Downregulation of Intercellular Adhesion Molecule-1 (ICAM-1) Abrogates Hepatic Metastases in Murine Colon Adenocarcinoma, Karen K. Lo, MD, University of Colorado, Aurora, CO
2012: Oral Paper 49: KRAS Codon 13 Mutations Predict Response to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma, Marjun Philip Duldulao, MD, City of Hope, Duarte, CA
2011: Oral Paper 69: Differential Expression of Colon Cancer Associated Transcript-1 (CCAT1) in the Adenoma-Carcinoma Sequence of the Colon and Rectum, Bilal Alaiyan, MD, Hadassah-Hebrew University Medical Center Mount Scopus, Jerusalem, Israel
Susan G. Komen® Breast Cancer Research Award
The SSO, in partnership with Susan G. Komen®, developed this award in 2015 to recognize excellence in research focused on breast cancer. The award will be made annually to a postdoctoral breast fellow or newly-trained surgical oncologist interested in breast cancer research whose work is being presented at the SSO Annual Cancer Symposium.2017: Oral Paper 8: CPS+EG and Neo-Bioscore are Superior Predictors of Overall Survival After Neoadjuvant Chemotherapy for Breast Cancer: A National Cancer Data Base Validation Study, John R. Bergquist, MD, MS, MA, Mayo Clinic, Rochester, MN
2016: Oral Paper 20: National Trends in the Use of Neoadjuvant Chemotherapy and Impact on Breast and Axillary Surgery in Hormone Receptor Negative Breast Cancer: A National Cancer Data Base Study, Carlos A. Puig, MD, Mayo Clinic, Rochester, MN
2015: Oral Paper 28: Prognostic Value of Combined Clinical and Pathologic Staging Variables in Predicting Local-Regional Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer, Mediget Teshome, MD, MPH, University of Texas MD Anderson Cancer Center, Houston, TX